全文获取类型
收费全文 | 775篇 |
免费 | 64篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 23篇 |
妇产科学 | 8篇 |
基础医学 | 70篇 |
口腔科学 | 13篇 |
临床医学 | 39篇 |
内科学 | 233篇 |
皮肤病学 | 23篇 |
神经病学 | 21篇 |
特种医学 | 63篇 |
外科学 | 29篇 |
综合类 | 32篇 |
预防医学 | 52篇 |
眼科学 | 41篇 |
药学 | 70篇 |
中国医学 | 9篇 |
肿瘤学 | 114篇 |
出版年
2023年 | 8篇 |
2022年 | 23篇 |
2021年 | 23篇 |
2020年 | 25篇 |
2019年 | 16篇 |
2018年 | 30篇 |
2017年 | 20篇 |
2016年 | 21篇 |
2015年 | 27篇 |
2014年 | 18篇 |
2013年 | 35篇 |
2012年 | 28篇 |
2011年 | 27篇 |
2010年 | 17篇 |
2009年 | 22篇 |
2008年 | 27篇 |
2007年 | 42篇 |
2006年 | 19篇 |
2005年 | 20篇 |
2004年 | 21篇 |
2003年 | 19篇 |
2002年 | 21篇 |
2001年 | 14篇 |
2000年 | 20篇 |
1999年 | 17篇 |
1998年 | 13篇 |
1997年 | 16篇 |
1996年 | 13篇 |
1995年 | 14篇 |
1994年 | 13篇 |
1993年 | 20篇 |
1992年 | 13篇 |
1991年 | 13篇 |
1990年 | 13篇 |
1989年 | 16篇 |
1988年 | 14篇 |
1987年 | 14篇 |
1986年 | 8篇 |
1983年 | 5篇 |
1982年 | 5篇 |
1981年 | 8篇 |
1980年 | 5篇 |
1979年 | 6篇 |
1978年 | 8篇 |
1975年 | 6篇 |
1974年 | 6篇 |
1973年 | 7篇 |
1972年 | 5篇 |
1971年 | 7篇 |
1967年 | 8篇 |
排序方式: 共有842条查询结果,搜索用时 325 毫秒
31.
Rong He Jonathan Chiou Allison Chiou Dong Chen Constance P. Chen Caroline Spethman Kurt R. Bessonen Jennifer L. Oliveira Phuong L. Nguyen Kaaren K. Reichard James D. Hoyer Simon D. Althoff Dana J. Roh Mechelle A. Miller Ji Yuan Horatiu Olteanu Kebede Begna Ayalew Tefferi Hassan Alkhateeb Mrinal M. Patnaik Mark R. Litzow Aref Al-Kali David S. Viswanatha 《Blood cancer journal》2022,12(1)
32.
33.
34.
35.
GK Resaland A Mamen SA Anderssen LB Andersen 《Acta paediatrica (Oslo, Norway : 1992)》2009,98(4):687-692
Aim: To describe cardiorespiratory fitness and body mass index (BMI) values in a representative population of 9-year-old Norwegian children in two rural communities and compare present values with previous findings.
Methods: Two hundred and fifty-nine 9-year-old children were invited, and 256 participated in this study. Maximal oxygen uptake was directly measured during a continuous progressive treadmill protocol. Body mass and height were also measured.
Results: The mean ± SD relative maximal oxygen uptake was 52.8 ± 6.5 for boys and 46.9 ± 7.2 mL/kg/min for girls. Eight percent of the boys and 16.8% of the girls were classified as overweight, and 1.6% of the boys and 6.9% of the girls as obese. Mean age, body mass, height and Ponderal index were not significantly different between sexes. Girls had a higher BMI than boys (p = 0.05).
Conclusion: Compared to earlier Norwegian studies, children's BMI values seem to have increased substantially. This increase is most pronounced in girls. When assessing these differences using the PI, this increase is less marked. Comparing maximal oxygen uptake data with that in earlier Nordic studies, there is no evidence that fitness has declined among 9-year olds. However, the limitations of the few earlier studies make reliable comparisons difficult. 相似文献
Methods: Two hundred and fifty-nine 9-year-old children were invited, and 256 participated in this study. Maximal oxygen uptake was directly measured during a continuous progressive treadmill protocol. Body mass and height were also measured.
Results: The mean ± SD relative maximal oxygen uptake was 52.8 ± 6.5 for boys and 46.9 ± 7.2 mL/kg/min for girls. Eight percent of the boys and 16.8% of the girls were classified as overweight, and 1.6% of the boys and 6.9% of the girls as obese. Mean age, body mass, height and Ponderal index were not significantly different between sexes. Girls had a higher BMI than boys (p = 0.05).
Conclusion: Compared to earlier Norwegian studies, children's BMI values seem to have increased substantially. This increase is most pronounced in girls. When assessing these differences using the PI, this increase is less marked. Comparing maximal oxygen uptake data with that in earlier Nordic studies, there is no evidence that fitness has declined among 9-year olds. However, the limitations of the few earlier studies make reliable comparisons difficult. 相似文献
36.
Julia S. Lehman MD Shahrukh K. Hashmi MD MPH Hillard M. Lazarus MD Rokea A. el‐Azhary MD PhD Lawrence E. Gibson MD William J. Hogan MD Mark R. Litzow MD Mrinal S. Patnaik MBBS Francis Buadi MD Martha Q. Lacy MD Surendra Dasari PhD Patrick Vanderboom MS Alexander Meves MD PhD 《Journal of cutaneous pathology》2017,44(12):1087-1091
37.
Sex determination is vital for the identification of an individual. Often fragmentary remains are available for forensic identification making sex determination difficult. The mastoid region, a fragmentary piece of skull, is ideal for studying sexual dimorphism as it is resistant to damage due to its anatomical position at the base of skull. The skull measurements vary significantly in different ethnic groups and the discrimination models for Indian populations are rare.In the present study, 60 adult human skulls of North Indian individuals were studied to determine accuracy of mastoid process in sex determination. Mastoid length, breadth and antero-posterior diameter of the mastoid process were measured to calculate the size of mastoid process.Discriminant function analysis revealed that mastoid process correctly classified the sex in 76.7% of the subjects and mastoid length was found to be the best determinant for sex although the classification rate dropped to 66.7%. A discriminant function equation specific for North Indian population has also been derived from mastoid variables. 相似文献
38.
A rapid and sensitive reverse phase high performance liquid chromatographic method is depicted for the qualitative and quantitative assay of letrozole in pharmaceutical dosage forms. Letrozole was chromatographed on a reverse phase C18 column with a mobile phase consisting of acetonitrile and phosphate buffer (pH 7.8) in the ratio of 70:30 v/v. The mobile phase was pumped at a flow rate of 1 ml/min. Acenaphthene was used as an internal standard and the eluents were monitored at 232 nm. The retention time of the drug was 3.385 min. With this method, linearity was observed in the range of 10-100 μg/ml. The LOD and LOQ were found to be 0.51 μg/ml and 1.52 μg/ml, respectively. The method was found to be applicable for analysis of drug in tablets. The results of the analysis were validated statistically. 相似文献
39.
Autoantibodies in early seropositive rheumatoid arthritis,before and during disease modifying antirheumatic drug treatment 总被引:1,自引:0,他引:1
Paulus HE Wiesner J Bulpitt KJ Patnaik M Law J Park GS Wong WK 《The Journal of rheumatology》2002,29(12):2513-2520
OBJECTIVE: Autoantibodies observed in patients with rheumatoid arthritis (RA) during clinical trials of immunomodulating agents may cause concern about possible induction of autoimmunity by the therapeutic intervention. We determined the frequency and variability of selected autoantibodies in patients with early rheumatoid factor (RF) positive RA during a prospective observational study. METHOD: The study cohort consisted of 276 patients with active RA and with RF > or = 40 IU, who were enrolled between January 1, 1993, and April 1, 2000, before starting disease modifying antirheumatic drug (DMARD) therapy (average duration of symptoms, 7 mo). During an average of 3.5 years followup, a panel of autoantibodies was determined at entry, 6 months, 12 months, and yearly thereafter, in addition to routine clinical, radiographic, and laboratory assessments. After enrollment, patients were treated with DMARD at the discretion of their rheumatologists. RESULTS: At entry before any DMARD therapy, antinuclear antibody (ANA; by HEp-2) values were negative in 31%, borderline (8 IU/ml) in 26%, and > 8 (mean 65.5 IU/ml) in 41%. Tender and swollen joint counts, Disease Activity Score, and RF values were significantly higher in those with ANA > 8. During followup 726 paired serial specimens were available; 12.5% changed from negative to positive ANA and 12.3% from positive to negative. Additional autoantibodies were present in specimens of 20% of the subjects; 8% had 2 and 1.4% had 3 other autoantibodies. Anti-dsDNA was detected in 13 (5.5%) patients; 4 changed from negative to positive and one from positive to negative. SSA IgG and SSB IgG autoantibodies were both present in one of these patients. Ribosomal P protein autoantibodies were noted in 2 other patients, but Sm (Smith) and uRNP/snRNP IgG autoantibodies were not present in any patient. No patient had a diagnosis of systemic lupus erythematosus. Antithyroid peroxidase (20 patients), parietal cell (15), smooth muscle (14), reticulin (9), mitochondrial (5), striational (2), SSB (2) and SCL-70 (1) autoantibodies were detected in some specimens. Seven patients were diagnosed with hypothyroidism, one with chronic thyroiditis, one with hepatitis C, and 9 with malignancies. CONCLUSION: In patients with early RF positive RA the frequent occurrence of autoantibodies before and during treatment with standard DMARD may make it difficult to attribute their presence to new therapies. 相似文献
40.
Amita Patnaik Debra Wood Anthony W Tolcher Marta Hamilton Jeffrey I Kreisberg Lisa A Hammond Garry Schwartz Muralidhar Beeram Manuel Hidalgo Monica M Mita Julie Wolf Paul Nadler Eric K Rowinsky 《Clinical cancer research》2006,12(24):7406-7413
PURPOSE: To assess the feasibility of administering erlotinib, an inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, in combination with paclitaxel and carboplatin, and to identify pharmacokinetic interactions, evaluate downstream effects of EGFR inhibition on surrogate tissues, and seek preliminary evidence for clinical activity. EXPERIMENTAL DESIGN: Patients with advanced solid malignancies were treated continuously with erlotinib at doses of 100, 125, and 150 mg/d orally along with fixed i.v. doses of paclitaxel 225 mg/m(2) and carboplatin AUC 6 mg x min/mL, both on day 1 every 3 weeks. RESULTS: Twenty evaluable patients were treated with 136 courses of erlotinib, paclitaxel, and carboplatin. Myelosuppression, skin rash, and diarrhea were the principal toxicities. Dose limiting diarrhea occurred in 1 of 6 patients at the 100 mg erlotinib dose level, whereas 0 of 9 evaluable patients at the 125 mg erlotinib dose level experienced dose limiting toxicity and 3 of 5 evaluable patients at 150 mg erlotinib experienced dose limiting skin rash and neutropenic sepsis. There was no evidence of pharmacokinetic interactions between paclitaxel and erlotinib; however, total carboplatin exposure trended higher in the presence of erlotinib. No consistent downstream effects on EGFR inhibition were found in skin. Durable objective responses were observed in non-small-cell lung and head and neck cancers. CONCLUSIONS: A dose level of erlotinib 125 mg combined with paclitaxel 225 mg/m(2) and carboplatin AUC 6 mg.min/mL is recommended for disease-directed studies. This phase I trial was followed by a randomized phase III study in non-small-cell lung cancer using a similar regimen. 相似文献